Global Chemiluminescence Immunoassay Market, by Product Type (Analyzers (Automated, Semi-automated), Reagents (Luminophore Markers, Enzymatic Markers), and Consumables), by Application (Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Disease, Autoimmune Disease, and Others), by End User ( Hospitals, Clinical Laboratories, Pharmaceutical and Biotechnology Companies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 6.01 billion in 2021, and is expected to exhibit a CAGR of 8.0 % during the forecast period (2021-2028).
Increasing number of product launches or approvals is expected to help in boosting growth of the global chemiluminescence immunoassay market. For instance, on February 22, 2021, Snibe Co. Ltd., a leading chemiluminescent immunoassay solution brand from Shenzhen, China, launched the CE-marked MAGLUMI SARSCoV2 Ag, a reliable chemiluminescent immunoassay solution for the quantitative detection of SARSCoV2 nucleocapsid antigens in patients with suspected COVID-19. The SARSCoV2 antigen test helps with the early detection of the SARSCoV2 virus in an acute COVID-19 infection.
Increase in number of acquisitions, partnerships, and collaborations between market players is expected to propel the growth of the global chemiluminescence immunoassay market during the forecast period. For instance, on November 24, 2020, Biomedical Advanced Research and Development Authority (BARDA), U.S. announced a partnership with Siemens Healthineers AG, a leading medical technology company, to boost up improvement of the SARS-CoV-2 Antigen assay (CoV2Ag). The CoV2Ag diagnostic test is a chemiluminescence immunoassay under development for the qualitative detection of SARSCoV2 antigens in nasal swabs or saliva samples from people with known or suspected exposure to the SARSCoV2 virus.
Global Chemiluminescence Immunoassay Market- Impact of Coronavirus (COVID – 19) Pandemic
The COVID-19 pandemic has affected several markets like elective surgeries, dermatology across the globe. The COVID-19 pandemic has affected the demand and supply of healthcare products in three main ways; by directly affecting the production and demand; by creating disruptions in distribution channels; and due to its financial impact on firms and financial markets.
However, impact of the coronavirus (COVID-19) pandemic is expected to drive the growth of the global chemiluminescence immunoassay market owing to increase in use of chemiluminescent immunoassays for detection of COVID-19 antibodies. For instance, according to the article published in the journal Frontiers in Immunology, December 2020, compared to Enzyme Linked Immuno-sorbent assay (ELISA) immunoassays, chemiluminescence immunoassays showed a significantly higher specificity score, but a lower sensitivity. It could be argued that chemiluminescence assays could be used as screening methods for the detection of anti-SARSCoV2 antibodies to assess the possible prevalence of the disease in the general population.
Browse 35 Market Data Tables and 25 Figures spread through 210 Pages and in-depth TOC on Global Chemiluminescence Immunoassay Market, by Product Type (Analyzers (Automated, Semi-automated), Reagents (Luminophore Markers, Enzymatic Markers), and Consumables), by Application (Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Disease, Autoimmune Disease, and Others), by End User ( Hospitals, Clinical Laboratories, Pharmaceutical and Biotechnology Companies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the global chemiluminescence immunoassay market, click the link below:
https://www.coherentmarketinsights.com/market-insight/chemiluminescence-immunoassay-market-4656
Key Takeaways of the Global Chemiluminescence Immunoassay Market:
- The global chemiluminescence immunoassay market is expected to exhibit a CAGR of 8.0 % over the forecast period (2021-2028). North America is expected to account for major market share over the forecast period (2021-2028) owing to the rising product approvals by regulatory authorities. For instance, on May 10, 2021, Inova Diagnostics, a global leader in reagent and autoimmune disease diagnostic systems for the clinical laboratory, announced the emergency approval of QUANTA Flash SARSCoV2 IgG from the U.S. Food and Drug Administration (FDA) for use in the BIOFLASH Random Access Chemiluminescent Analyzer.
- Some of the major players operating in the global chemiluminescence immunoassay market include DiaSorin S.p.A., Abbott Laboratories, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers, Beckman Coulter Inc., F. Hoffmann-La Roche AG, Inova Diagnostics, Inc., Maccura Biotechnology Co., Ltd., Tosoh Corporation, and Ortho Clinical Diagnostic.
